



April 20, 2006

Enzon To Present At UBS Warburg Global Life Sciences Conference

Bridgewater, New Jersey – April 20, 2006 – Enzon Pharmaceuticals, Inc. (Nasdaq: ENZN) announced today that Jeffrey H. Buchalter, Enzon's chairman and chief executive officer, will present at the UBS Warburg Global Life Sciences Conference, which is being held April 24 to 25 in New York City. Enzon's presentation will take place at 8:30 a.m. EDT on Tuesday, April 25, 2006. The presentation will be webcast. Interested parties can access the webcast information by going to the events page that is under shareholder information on Enzon's website at www.enzon.com.

About Enzon

Enzon Pharmaceuticals, Inc. is a biopharmaceutical company dedicated to the development and commercialization of therapeutics to treat patients with cancer and other life-threatening diseases. Enzon's specialized sales force markets ABELCET®, ADAGEN®, DEPOCYT®, and ONCASPAR® in North America. In addition, Enzon also receives royalties on sales of PEG-INTRON®, marketed by Schering-Plough Corporation, and MACUGEN®, marketed by OSI Pharmaceuticals and Pfizer Inc. Enzon's product-driven strategy includes an extensive drug development program that leverages its proprietary technologies, including a next-generation PEGylation platform that utilizes linkers designed to release compounds at a controlled rate. Enzon complements its internal research and development efforts with strategic initiatives, such as partnerships designed to broaden its revenue base or provide access to promising new technologies or product development opportunities. Further information about Enzon and this press release can be found on the Company's web site at www.enzon.com.

All information in this press release is as of April 20, 2006 and the Company undertakes no duty to update this information.

Contacts:

Craig Tooman
EVP, Finance & CFO
908-541-8777